Physician profile
Jeffrey D Bruning
NPI 1689056681
$7,360.62
in general payments reported to CMS, 2019-2025
40 companies · $1,993 in 2025
The $1,993 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.85 · 2020: $358 · 2021: $899 · 2022: $1,342 · 2023: $1,553 · 2024: $1,179 · 2025: $1,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,704 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,704.31 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,915.44 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,218.86 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $564.02 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $515.75 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $505.10 | 2020-2025 | Evenity, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $396.68 | 2022-2025 | |
| Astellas Pharma US INC | $182.88 | 2023-2025 | Veozah |
| Pfizer INC. | $172.13 | 2022-2025 | |
| Lilly USA, LLC | $168.25 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $162.79 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $158.99 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.67 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $146.24 | 2025 | Symbravo, Auvelity |
| Sumitomo Pharma America, INC. | $124.12 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.31 | 2023-2025 | Xifaxan, Trulance |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Bruning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.